Abstract | BACKGROUND AND PURPOSE: METHODS: The medical records of several patients from Robert Wood Johnson University Hospital, with previously treated breast cancer admitted for therapy for AML or myelodysplasia, were reviewed. In addition, the recent literature on this topic was reviewed. RESULTS: CONCLUSIONS:
Chemotherapy and radiation therapy administered for breast cancer predispose patients to the development of MDS or AML. We hypothesize that the breast cancer (BRCA) gene mutations might add to the risk and that primary care physicians must be aware of the long-term risks of cytotoxic therapy, including the development of MDS or AML.
|
Authors | Marion Cole, Roger Strair |
Journal | The American journal of the medical sciences
(Am J Med Sci)
Vol. 339
Issue 1
Pg. 36-40
(Jan 2010)
ISSN: 1538-2990 [Electronic] United States |
PMID | 19996729
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Alkylating
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Alkylating
(adverse effects)
- Breast Neoplasms
(drug therapy, radiotherapy)
- Female
- Humans
- Leukemia, Myeloid, Acute
(chemically induced, etiology)
- Middle Aged
- Myelodysplastic Syndromes
(chemically induced, etiology)
|